MacMillan TE, et al. - The outcomes in hyponatremia based on desmopressin (DDAVP) usage are compared in this study. Though it is observational, this information supports a reactive strategy for utilizing DDAVP in patients at average risk of osmotic demyelination syndrome and also a more stringent plasma sodium correction limit of 8 mEq/L in any 24-hour period for high-risk patients. Further studies are urgently required on DDAVP use in treating hyponatremia.